Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy?
作者信息
Wagner Bradley G, Kahn James S, Blower Sally
出版信息
AIDS. 2010 Mar 13;24(5):775-6. doi: 10.1097/QAD.0b013e3283366782.
Abstract
摘要
相似文献
1
Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy?
AIDS. 2010 Mar 13;24(5):775-6. doi: 10.1097/QAD.0b013e3283366782.
2
Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings.
AIDS. 2010 Mar 13;24(5):729-35. doi: 10.1097/QAD.0b013e32833433fe.
3
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.
Ann Intern Med. 2010 Dec 21;153(12):778-89. doi: 10.7326/0003-4819-153-12-201012210-00004.
4
Scaling Up Human Immunodeficiency Virus Screening and Antiretroviral Therapy Among Men Who Have Sex With Men to Achieve the 90-90-90 Targets in China.
Sex Transm Dis. 2018 May;45(5):343-349. doi: 10.1097/OLQ.0000000000000744.
5
Cost-effectiveness analysis of 'test and treat' policy for antiretroviral therapy among heterosexual HIV population in India.
Indian J Med Res. 2022 Jun;156(6):705-714. doi: 10.4103/ijmr.IJMR_806_20.
6
Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
J Gen Intern Med. 2013 Oct;28(10):1294-301. doi: 10.1007/s11606-013-2417-1. Epub 2013 Apr 16.
7
Age-targeted HIV treatment and primary prevention as a 'ring fence' to efficiently interrupt the age patterns of transmission in generalized epidemic settings in South Africa.
Int Health. 2016 Jul;8(4):277-85. doi: 10.1093/inthealth/ihw010. Epub 2016 Mar 23.
8
HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis.
PLoS One. 2011;6(11):e27625. doi: 10.1371/journal.pone.0027625. Epub 2011 Nov 16.
9
Assessing characteristics of hidden epidemics to design the most efficient HIV testing strategies.
AIDS. 2014 Jul 31;28(12):1831-3. doi: 10.1097/QAD.0000000000000271.
10
Cost-effectiveness of voluntary HIV screening in Russia.
Int J STD AIDS. 2009 Jan;20(1):46-51. doi: 10.1258/ijsa.2008.008128.
引用本文的文献
1
Re-engagement and retention in HIV care after preventive default tracking in a cohort of HIV-infected patients in rural Malawi: A mixed-methods study.
PLOS Glob Public Health. 2024 Feb 21;4(2):e0002437. doi: 10.1371/journal.pgph.0002437. eCollection 2024.
2
HIV prevalence among men who have sex with men in Brazil: results of the 2nd national survey using respondent-driven sampling.
Medicine (Baltimore). 2018 May;97(1S Suppl 1):S9-S15. doi: 10.1097/MD.0000000000010573.
3
Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis.
Am J Epidemiol. 2016 Aug 1;184(3):239-48. doi: 10.1093/aje/kwv344. Epub 2016 Jul 13.
4
Evaluating the Impact of Test-and-Treat on the HIV Epidemic among MSM in China Using a Mathematical Model.
PLoS One. 2015 Jun 3;10(6):e0126893. doi: 10.1371/journal.pone.0126893. eCollection 2015.
5
6
Are Low- and Middle-Income Countries Repeating Mistakes Made by High-Income Countries in the Control of HIV for Men who have Sex with Men?
J AIDS Clin Res. 2012;Suppl 4:e001. doi: 10.4172/2155-6113.S4-e001.
7
Massive benefits of antiretroviral therapy in Africa.
J Infect Dis. 2014 Feb 15;209(4):483-5. doi: 10.1093/infdis/jit586. Epub 2013 Dec 3.
8
Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study.
PLoS Med. 2013 Oct;10(10):e1001534. doi: 10.1371/journal.pmed.1001534. Epub 2013 Oct 22.
9
Balancing efficiency, equity and feasibility of HIV treatment in South Africa - development of programmatic guidance.
Cost Eff Resour Alloc. 2013 Oct 9;11(1):26. doi: 10.1186/1478-7547-11-26.
10
Prospects of elimination of HIV with test-and-treat strategy.
Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15538-43. doi: 10.1073/pnas.1301801110. Epub 2013 Sep 5.
本文引用的文献
1
Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings.
AIDS. 2010 Mar 13;24(5):729-35. doi: 10.1097/QAD.0b013e32833433fe.
2
When to start antiretroviral therapy in resource-limited settings.
Ann Intern Med. 2009 Aug 4;151(3):157-66. doi: 10.7326/0003-4819-151-3-200908040-00138. Epub 2009 Jul 20.
3
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8.
4
Effect of early versus deferred antiretroviral therapy for HIV on survival.
N Engl J Med. 2009 Apr 30;360(18):1815-26. doi: 10.1056/NEJMoa0807252. Epub 2009 Apr 1.
5
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.
Lancet. 2009 Jan 3;373(9657):48-57. doi: 10.1016/S0140-6736(08)61697-9. Epub 2008 Nov 27.
6
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.
7
Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.
AIDS. 2006 Aug 1;20(12):1605-12. doi: 10.1097/01.aids.0000238406.93249.cd.
8
Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?
Lancet Infect Dis. 2002 Aug;2(8):487-93. doi: 10.1016/s1473-3099(02)00346-8.
9
A tale of two futures: HIV and antiretroviral therapy in San Francisco.
Science. 2000 Jan 28;287(5453):650-4. doi: 10.1126/science.287.5453.650.
Zotero 插件